Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease.

Trial Profile

Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2012

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical dysplasia; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top